Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets.

Monica F Chen Soo-Ryum Yang Jessica J Tao Antoine Desilets Eli L Diamond Clare J Wilhem Ezra Y Rosen Yixiao Gong Kerry Mullaney Jean Torrisi Robert J Young Romel Somwar Helena Alexandra Yu Mark G Kris Gregory J Riely Maria E Arcila Marc Ladanyi Mark T A Donoghue Neal X Rosen Rona Yaeger Alexander E Drilon Yonina R Murciano-Goroff Michael D Offin

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

BRAF fusions are found across histologies and represent an emerging actionable target. BRAF fusions have a diverse set of fusion partners. Durable responses to MAPK therapies were seen, particularly in pilocytic astrocytomas. Acquired BRAF fusions were identified after targeted therapy, underscoring the importance of postprogression biopsies to optimize treatment at relapse in these patients.

Keyphrases

metastatic colorectal cancer
wild type
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
signaling pathway
oxidative stress
gene expression
copy number
pi k akt
patient reported outcomes
combination therapy
human immunodeficiency virus
hepatitis c virus